OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, April 04, 2012

financial news: Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test (OvaDx)



Arrayit Diagnostics, Inc. Reports Results of Research Study for Ovarian Cancer Diagnostic Test

" Arrayit Corporation and Arrayit Diagnostics, Inc. ("AD") report significant results from a 257 patient research study on its pre-symptomatic ovarian cancer molecular diagnostic test in development, OvaDx(R). In this study, OvaDx(R) recorded sensitivity of 79.7%, correctly identifying patients known to have cancer, and specificity approaching 100%, correctly identifying the healthy controls, patients known not to have cancer......

NCCN.com - Evidence-Based Cancer Guidelines and Treatment Summaries for Patients (sundry topics)



NCCN.com - Evidence-Based Cancer Guidelines and Treatment Summaries for Patients

NCCN.com Puts the Focus on Living With Cancer...

VIDEO: How to Maintain Good Bone Health During Cancer Treatment

NCCN Guidelines: Ovarian Cancer March 2012



Blogger's Note: the pdf link below requires registration (free), alternatively go to: http://www.nccn.org and click on guidelines 3/2012 version shows (pages 4/5) changes from 2/2012  version; most recent version includes 'language' changes, category recommendations (eg. highly recommended, neoadjuvant therapy, CA125/clinical relapse/re-treatment, LMP, fertility issues, 'malignant' sex chord stromal, stage 1 added (stages 11-1V) to certain pages....) 

NCCN Guidelines: Ovarian Cancer 2012

Phase 2 Study Update of Selumetinib for Ovarian Cancer - MPR



Blogger's Note: more info req'd eg. side effects....

Phase 2 Study Update of Selumetinib for Ovarian Cancer - MPR

Array BioPharma announced results of a Phase 2 trial of selumetinib in women with recurrent low-grade serous ovarian or peritoneal cancer.

In the trial, 52 women each received 100mg doses of selumetinib orally twice daily in four-week cycles until disease progression or toxicity. The median number of cycles received was 4.5; 33% underwent ≥12 cycles. Prior to the trial, 58% of the patients in the trial had received three or more rounds of chemotherapy.

A disease control rate, defined as either complete or partial response or progression-free survival or progression-free survival of greater than 6 months, occurred in 81% of patients. Eight patients had complete (1) or partial (7) responses, and 34 (63%) had progression-free survival of >6 months. The median survival rate without cancer progression was 11 months.

Selumetinib is an anti-cancer drug in Phase 2 development in a range of tumors. It is a small molecule MEK inhibitor that targets a key position in the Ras-Raf-MEK-ERK signaling pathway. MEK has been shown to be frequently activated in cancer, in particular in tumors that have mutations in the RAS and RAF pathways.

For more information call (877) MED-CHEM or visit www.arraybiopharma.com

abstract: Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer - Segelman - 2012 - British Journal of Surgery - Wiley Online Library




Peritoneal Carcinomatosis (Creighton University) includes a variety of tumors that present with extensive metastasis throughout the peritoneal cavity (inside surface of the abdomen) and can be found with gall bladder, liver, colon, appendix, ovarian, pancreas, mesothelioma, pseudomyxoma peritonei, rectal, small bowel and stomach cancers. It is a broad description in which multiple tumors develop in and line the peritoneal abdominal cavity and linings.

          ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

 Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer - Segelman - 2012 - British Journal of Surgery

Abstract

Background:

This was a population-based cohort study to determine the incidence, prevalence and risk factors for peritoneal carcinomatosis (PC) from colorectal cancer.

Methods:

Prospectively collected data were obtained from the Regional Quality Registry. The Cox proportional hazards regression model was used for multivariable analysis of clinicopathological factors to determine independent predictors of PC.

Results:

All 11 124 patients with colorectal cancer in Stockholm County during 1995–2007 were included and followed until 2010. In total, 924 patients (8·3 per cent) had synchronous or metachronous PC. PC was the first and only localization of metastases in 535 patients (4·8 per cent). The prevalence of synchronous PC was 4·3 per cent (477 of 11 124). The cumulative incidence of metachronous PC was 4·2 per cent (447 of 10 646). Independent predictors for metachronous PC were colonic cancer (hazard ratio (HR) 1·77, 95 per cent confidence interval 1·31 to 2·39; P = 0·002 for right-sided colonic cancer), advanced tumour (T) status (HR 9·98, 3·10 to 32·11; P < 0·001 for T4), advanced node (N) status (HR 7·41, 4·78 to 11·51; P < 0·001 for N2 with fewer than 12 lymph nodes examined), emergency surgery (HR 2·11, 1·66 to 2·69; P < 0·001) and non-radical resection of the primary tumour (HR 2·75, 2·10 to 3·61; P < 0·001 for R2 resection). Patients aged > 70 years had a decreased risk of metachronous PC (HR 0·69, 0·55 to 0·87; P = 0·003).

Conclusion:

PC is common in patients with colorectal cancer and is associated with identifiable risk factors.

Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients



Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients:

Background:
Patients with active cancer are often on chronic anticoagulation and frequently require interruption of this treatment for invasive procedures. The impact of cancer on periprocedural thromboembolism (TE) and major bleeding is not known.

Patients and methods:
Two thousand one hundred and eighty-two consecutive patients referred for periprocedural anticoagulation (2484 procedures) using a standardized protocol were followed forward in time to estimate the 3-month incidence of TE, major bleeding and survival stratified by anticoagulation indication. For each indication, we tested active cancer and bridging heparin therapy as potential predictors of TE and major bleeding.

Results:
Compared with patients without cancer, active cancer patients (n = 493) had more venous thromboembolism (VTE) complications (1.2% versus 0.2%), major bleeding (3.4% versus 1.7%) and reduced survival (95% versus 99%). Among active cancer patients, only those chronically anticoagulated for VTE had higher rates of periprocedural VTE (2% versus 0.16%;) and major bleeding (3.7% versus 0.6%). Bridging with heparin increased the rate of major bleeding in cancer patients (5% versus 1%;) without impacting the VTE rate (0.7% versus 1.4%,).

Conclusions:
Cancer patients anticoagulated for VTE experience higher rates of periprocedural VTE and major bleeding. Periprocedural anticoagulation for these patients requires particular attention to reduce these complications.

abstract: Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries?



Blogger's Note: paid subscription required to view full paper, the 'burning' question in the abstract is what other 7 cancers ??
                           ~~~~~~~~~~~~~~~~~~

Cancer of unknown primary (CUP): does cause of death and family history implicate hidden phenotypically changed primaries?

Abstract

Background: Cancer of unknown primary (CUP) is diagnosed at the metastatic stage. We aimed to identify hidden primary cancers in CUP patients by comparison with cancers in family members. We take use of the fact that the cause of death in CUP patients is often coded as the cancer in the organ of fatal metastasis. 

Patients and methods: Forty-one thousand five hundred and twenty-three CUP patients were identified in the Swedish Family-Cancer Database, and relative risks (RRs) were calculated for cancer in offspring when family members were diagnosed with CUP and died of the cancer diagnosed in offspring. 

Results: The RR for lung cancer in offspring was 1.85 when a family member was diagnosed with CUP and died of lung cancer. Significant familial associations were found for seven other cancers. Many familial associations were also significant when offspring CUP patients died of the cancer diagnosed in family members. 

Conclusions: The cause of death after CUP diagnosis frequently matched the cancer found in a family member, suggesting that the CUP had originated in that tissue. The metastasis had probably undergone a phenotypic change, complicating pathological tissue assignment. These novel data suggest that some CUP cases are phenotypically modified primary cancers rather than cancers of unknown primaries.

Talking to Your Child About Cancer - MD Anderson



Talking to Your Child About Cancer

A cancer diagnosis can create a variety of questions for patients who have children. The first question many parents ask is, "How do I talk to my child about cancer?"

Whether you're wondering how to tell your child about your diagnosis, treatment, progression or recurrence, there are quite a few things to consider before beginning these important discussions.

To start, consider your child's age and developmental stage. Some children are too young to verbalize questions and others may be too afraid to ask. Also, what does your child already know about cancer?

What is the best approach?
It's common for parents to protect their children by withholding information that may be upsetting, but research shows the following:
  1. A parent's cancer diagnosis affects a child whether or not the child is informed of the condition. 1
  2. Anxiety levels are higher in children who aren't informed about their parent's condition, compared to children where the issue is discussed.
  3. For parents of teenagers, an important aspect of coping is ongoing communication between the teens and their parents during the course of the illness. 2
So, what does this research mean to parents? Simply put, it means that honest, age-appropriate communication is best. How do I talk to my child about cancer?
First, it's crucial to say the word "cancer." This is essential so the child will not associate the parent's diagnosis with another illness children can catch, like the flu or a cold. The following are common questions many children have, and they're important points to consider while talking with your child:
  • Can I catch cancer?
  • How does cancer happen?
  • Is it my fault my mom or dad got cancer?
  • Will my mom or dad die from cancer?
Remember that children may not ask these outright, but many will be wondering about them. Because children pick up on social cues, they may sometimes create scenarios in their heads far worse than reality when not given honest communication about what's happening.

Honest and age-appropriate communication with children models the behavior that it's OK to ask and talk about cancer. 

further details: FDA MedWatch - Altuzan (bevacizumab): Counterfeit Product - Contains no Active Ingredient



Subject: Apr 3rd FDA MedWatch - Altuzan (bevacizumab): Counterfeit Product - Contains no Active Ingredient

Altuzan (bevacizumab): Counterfeit Product - Contains no Active Ingredient


ISSUE: FDA lab tests have confirmed that a counterfeit version of Roche’s Altuzan 400mg/16ml (bevacizumab),an injectable cancer medication, found in the U.S. contains no active ingredient. Even if the identified drugs were not counterfeit, Altuzan is not approved by FDA for use in the United States (it is an approved drug in Turkey).

BACKGROUND: Medical practices obtained the counterfeit Altuzan and other unapproved products through foreign sources, in particular from Richards Pharma, also known as Richards Services, Warwick Healthcare Solutions, or Ban Dune Marketing Inc (BDMI).  Many, if not all, of the products sold and distributed through this distributor have not been approved by the FDA. Pictures of the counterfeit version of Altuzan are shown in the FDA statement. Packaging or vials found in the U.S. that claim to be Roche’s Altuzan with lot number B6021 should be considered counterfeit.
RECOMMENDATION: Any medical practice that has obtained unapproved products, in particular from Richards Pharma, Richards Services, Warwick Healthcare Solutions, or Ban Dune Marketing Inc (BDMI), should stop using them and contact the FDA.  The products should be retained and securely stored until further notice by the FDA.
FDA is asking the public to report suspect counterfeit products and other suspect products obtained from Richards Pharma, Richards Services, Warwick Healthcare Solutions, Ban Dune Marketing Inc (BDMI), or other sources:
Call FDA’s Office of Criminal Investigations (OCI) at 800-551-3989, or  
Visit OCI’s Web site (www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm), or
Email - DrugSupplyChainIntegrity@fda.hhs.gov

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
  • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Read the MedWatch safety alert, including links to the FDA statement, at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm298583.htm

You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm

5 Health Problems Linked to Height - ABC News



5 Health Problems Linked to Height - ABC News

 5 Health Problems Linked to Height

Cancer
A new study suggests taller women have heightened risk for ovarian cancer, a disease that kills nearly 15,000 American women each year, according to the U.S. Centers for Disease Control and Prevention.
British researchers reviewed data from 47 studies involving more than 100,000 women. For every 5-centimeter (2-inch) increase in height above the average 5 feet 3, the risk of ovarian cancer rose 7 percent, according to the study published Tuesday in the journal PLoS Medicine.
In July 2011, a study published in the Lancet Oncology found taller women had an increased risk of 10 different cancers, including breast and skin cancer. And taller men have an increased risk of prostate cancer, according to a 2008 study published in the journal Cancer Epidemiology, Biomarkers & Prevention.
"One of the big surprises in cancer has been the potential impact of early life nutritional factors on long-term cancer risk," said Dr. Tim Byers, a professor of preventive medicine and biometrics at the University of Colorado Cancer Center in Denver. "I think height is an indicator of some risk factor, but we don't know what the mechanism is."
The findings offer little comfort for tall men and women, whose height -- guided by genes, nutrition and other environmental influences -- was established in their 20s. But Byers said taller people should not worry any more, nor should shorter people worry any less, about their cancer risk.

Heart Disease

Stroke

Alzheimer's Disease

Diabetes  



open access: Apr 3 - PLoS Medicine: Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies



 Published: April 3, 2012

PLoS Medicine: Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies

Background

Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships.........

Why Was This Study Done?

To date, there is no definitive information about the relevance of women's height, weight, and body mass index to their subsequent risk of developing ovarian cancer. There have been roughly 50 epidemiological studies of ovarian cancer, but only about half of these studies have published results on the association between body size and ovarian cancer risk, and so far, these findings have been inconsistent. Therefore, the researchers—an international collaboration of researchers studying ovarian cancer—re-analyzed the available epidemiological evidence to investigate the relationship between ovarian cancer risk and adult height, weight, and body mass index, and to examine the consistency of the findings across study designs.

Conclusions

Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade.



Lists - Choosingwisely - "Five Things Physicians and Patients Should Question" 9 U.S. specialty society lists (gyn oncology is not specifically listed)



Lists - Choosingwisely

Lists

Nine United States specialty societies representing 374,000 physicians developed lists of "Five Things Physicians and Patients Should Question" in recognition of the importance of physician and patient conversations to improve care and eliminate unnecessary tests and procedures.
These lists represent specific, evidence-based recommendations physicians and patients should discuss to help make wise decisions about the most appropriate care based on their individual situation. Each list provides information on when tests and procedures may be appropriate, as well as the methodology used in its creation.
What tests and procedures should patients and physicians talk about? Read the lists:

open access: Microsatellite Instability and DNA Mismatch Repair Protein Deficiency in Lynch Syndrome Colorectal Polyps - multinational study



Blogger's Note: as determined by the title, focus is on colorectal cancer in Lynch Syndrome; see also prior posting Diagnosing Lynch Syndrome: More Light at the End of the Tunnel which gives a more comprehensive overall view of Lynch Syndrome

                           ~~~~~~~~~~~~~~~~~

Microsatellite Instability and DNA Mismatch Repair Protein Deficiency in Lynch Syndrome Colorectal Polyps

"Lynch syndrome results from germline mutations in one
of the genes involved with DNA mismatch repair (MMR):
MLH1, MSH2, MSH6, PMS2, or EPCAM/TACSTD."

"The aim of this study was to determine the prevalence
of MSI and loss of MMR protein expression by immunohistochemistry
in colorectal polyps from patients with genetically confirmed Lynch syndrome."






open access: Perspectives - Diagnosing Lynch Syndrome: More Light at the End of the Tunnel



Diagnosing Lynch Syndrome: More Light at the End of the Tunnel

"Lynch syndrome is one of the most commonly inherited
cancer conditions, accounting for 2% to 4% of colorectal
cancer (CRC) cases. The population frequency of Lynch
syndrome is slightly more than one in 500 individuals (1).
In addition to a 50% to 80% lifetime risk of CRC, patients
with Lynch syndrome have a 40% to 60% risk of uterine
cancer and an elevated risk of ovarian, pancreatic, gastric,
upper-urinary tract, renal, biliary, small bowel, and central
nervous system (CNS) malignancies.

"Colorectal surveillance of persons with this condition leads to greatly reduced CRC incidence and mortality. Appropriately timed hysterectomy and ovarectomy likewise results in a reduced incidence of malignancies in these organs. The diagnosis of Lynch syndrome is thus critical to the prevention and early detection of cancer in affected persons and families, notwithstanding that the effectiveness of screening patients with Lynch syndrome for non colorectal and non uterine malignancies remains uncertain. As will be discussed later, the article by Yurgelun and colleagues in this issue of the journal provides an important new tool for the diagnosis of Lynch syndrome (2).
The major issue in Lynch syndrome remains failure to
diagnose for a variety of reasons......."

".....It seems that MSI or immunohistochemical
testing in uterine cancers may be as effective as in
CRCs and therefore should also be considered in evaluating
persons and families for Lynch syndrome (17, 18). Whether
tumor testing in other (nonuterine or noncolorectal)
Lynch-associated malignancies would be as effective is
unclear....."

"............Next generation sequencing also may soon
be available for individual testing at reasonable costs.
Such new testing developments may well make direct-to-genetic
testing based on risk increasingly attractive. At
some point, general testing for an inherited syndrome
without regard to risk may even become a reality, which would get the diagnosis of Lynch syndrome out of the tunnel altogether."

open access: American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology



American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs The Top Five List for Oncology

 1. Do not use cancer-directed therapy for patients with solid tumors
who have the following characteristics: low performance status (3 or 4), no benefit from prior evidence-based interventions, not eligible for a clinical trial, and with no strong evidence supporting the clinical value of further anticancer treatment.
2. Don’t perform PET, CT and radionuclide bone scans in the staging of early prostate cancer at low risk for metastasis.
3. Don’t perform PET, CT and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis
4. Don’t perform surveillance testing (biomarkers) or imaging (PET, CT and radionuclide bone scans) for asymptomatic individuals who have been treated for breast cancer with curative intent.
5. Don’t use white cell stimulating factors for primary prevention of febrile neutropenia for patients with less than 20% risk for this complication

Tuesday, April 03, 2012

Apr 3rd early release: United States Cancer Statistics Public Information Data - Cancer Statiistics (searchable by organ site/state/age....)



United States Cancer Statistics Public Information Data

CDC's Division of Cancer Prevention and Control is pleased to announce the early release of National Program of Cancer Registries (NPCR) cancer incidence data for the years 1999–2009 to facilitate cancer control planning. The data are available through CDC WONDER at http://wonder.cdc.gov/cancer.html.
The data from selected NPCR registries cover between 86% and 96% of the United States population, depending on the specific year of diagnosis. This release is part of the NPCR Data Release Plan and is based on the NPCR Cancer Surveillance System 2012 data submission.
CDC WONDER is an online query system that produces age-adjusted and crude rates in tabular, map, and chart formats. Variables include year of diagnosis, state, region or division of the United States, sex, race, ethnicity, age, primary site, and childhood cancer.



National Program of Cancer Registries (NPCR)
Division of Cancer Prevention and Control (DCPC)
Centers for Disease Control and Prevention (CDC)

abstract: Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden.



Blogger's Note: see also posting regarding BRCA1/heart disease/doxorubicin research... (blog posting Apr 3 eg. as per below abnormal lipid levels/ovarian cancer)

                ~~~~~~~~~~~~~~~~

Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden.

Abstract

OBJECTIVE:

To study how the incidence of cancer is related to diabetes, obesity or abnormal blood lipids.

METHODS:

Diagnosis of diabetes, obesity or abnormal blood lipids was studied 0-10 years prior to the diagnosis of cancer in 19,756 cases of cancer and in 147,324 controls matched regarding age, sex and domicile.

RESULTS:

Diabetes was significantly more common prior to diagnosis in patients with liver, pancreatic, colon and urinary tract/bladder cancer and in patients with breast cancer diagnosed with diabetes 0-4 years prior to the cancer diagnosis. A lower risk of diabetes was seen in patients with prostate carcinoma among individuals with diabetes diagnosed 5-10 years prior to the cancer diagnosis. The findings remained after adjusting for obesity and high blood lipids. Obesity was significantly more common in patients with endometrial, colon and kidney cancer and with breast cancer above the age of 60 years in those where obesity was diagnosed close to the diagnosis of cancer. High blood lipids were significantly more common in patients with ovarian cancer and less common in patients with breast cancer.

CONCLUSIONS:

The study confirms some previous findings concerning comorbidity and cancer and highlights some new ones.

abstract: Study: Vast Majority of C difficile Infections Occur in Medical Settings, April 4, 2012, Voelker 307 (13): 1356 — JAMA



Study: Vast Majority of C difficile Infections Occur in Medical Settings, April 4, 2012

    Most Clostridium difficile infections, often assumed to be community acquired, actually occur in medical settings, according to recent data from the Centers for Disease Control and Prevention (CDC). 

    In fact, 94% of the potentially fatal infections are in people who recently received care in facilities such as hospitals, nursing homes, physicians' offices, and outpatient surgical centers. To stem the rising tide of C difficile infections, CDC officials say hospitals and other health care settings need greater adherence to infection control practices and improved communication to notify each other whenever they transfer an infected patient. 

    “These infections are now a patient safety concern everywhere medical care is given,” said Clifford McDonald, MD, a CDC medical epidemiologist and lead author of the study in the Morbidity and Mortality Weekly Report (http://tinyurl.com/7dh83hh). “About 25% of C difficile infections first show symptoms among patients in hospitals; 75% first show symptoms among patients in nursing …"


    abstract: Rare Mutations in XRCC2 Increase the Risk of Breast Cancer.



     Blogger's Note: see recent post for a null finding XRCC/Lynch Syndrome

    Rare Mutations in XRCC2 Increase the Risk of Breast Cancer.:

    Rare Mutations in XRCC2 Increase the Risk of Breast Cancer.

    Am J Hum Genet. 2012 Mar 28;


    Abstract

    An exome-sequencing study of families with multiple breast-cancer-affected individuals identified two families with XRCC2 mutations, one with a protein-truncating mutation and one with a probably deleterious missense mutation. We performed a population-based case-control mutation-screening study that identified six probably pathogenic coding variants in 1,308 cases with early-onset breast cancer and no variants in 1,120 controls (the severity grading was p<0.02). We also performed additional mutation screening in 689 multiple-case families. We identified ten breast-cancer-affected families with protein-truncating or probably deleterious rare missense variants in XRCC2. Our identification of XRCC2 as a breast cancer susceptibility gene thus increases the proportion of breast cancers that are associated with homologous recombination-DNA-repair dysfunction and Fanconi anemia and could therefore benefit from specific targeted treatments such as PARP (poly ADP ribose polymerase) inhibitors. This study demonstrates the power of massively parallel sequencing for discovering susceptibility genes for common, complex diseases.



    Cancer Fact or Fiction: Separating Myths from Good Information -- BETHESDA, Md., April 3, 2012 /PRNewswire-USNewswire/ --



    Cancer Fact or Fiction: Separating Myths from Good Information -- BETHESDA, Md., April 3, 2012 /PRNewswire-USNewswire/

    By the National Cancer Institute

    Translations: Español


    BETHESDA, Md., April 3, 2012 /PRNewswire-USNewswire/ -- To many, cancer remains one of the most frightening diagnoses in modern medicine. But much of this fear is a result of myths that have circulated for years in spite of the good information that is available. Indeed, many of cancer's mysteries have been solved, and a great deal of success has been achieved in curing patients and helping them live longer and better lives. Despite advances in cancer treatment and prognosis, many continue to believe in myths surrounding cancer. In particular, studies have shown that Hispanics are more likely than whites to maintain some erroneous beliefs about cancer.


    It is important to separate fact from fiction. Some of the most common cancer myths not only cultivate false ideas and fears but also can interfere with how people think and behave when facing cancer in themselves or in a loved one. It is important that the health messengers within the family and community have the most accurate information about cancer. In many Hispanic families, that is often the woman running the household. It is good for these health messengers and the people who listen to them to at least be aware of some of the most common cancer myths so that misinformation doesn't stand in the way of getting counsel from a medical professional.

    What Will Happen to Me If I Get Cancer?Myth––Cancer is a death sentence. The fact is that more than 12 million cancer survivors are living in the United States. Thanks to improved treatments and earlier diagnosis of some cancers, more than 3 of every 5 cancer patients are alive 5 years after their diagnosis. For children, the 5-year survival rate is 4 in 5.

    Who Gets Cancer and WhyMyth––Cancer is contagious. You cannot catch cancer from someone who has it. What can spread among people are microorganisms (viruses and bacteria), and a few of these can cause cancer. Recent Hispanic immigrants may have a greater risk of some cancers caused by infectious agents if there was a higher prevalence of related infections in their country of origin.

    Myth––If a parent or close family member had cancer, you will inherit it. Cancer develops when genes change in certain ways, but most of these changes occur during a person's lifetime and are not inherited. But some cancer-causing gene changes are inherited, so if a certain cancer seems to run in your family it is important to discuss this with a doctor.

    Myth––People get cancer from . . . (just fill in the blank as to what you have heard). Scientists are continuously doing research to determine whether particular natural or manmade substances cause cancer. Research shows that the following are not likely to cause cancer: cell phones, microwaves, fluoridated water, hair dyes, deodorants, sugar, artificial sweeteners like saccharin and aspartame, and low-frequency magnetic fields produced by power lines and household electric appliances.

    What You Can Do About It Myth––You have no control over your own cancer risk. Although scientists haven't figured out how to completely prevent cancer, there are things you can do to reduce your risk of certain cancers. For example:
    • Not smoking or quitting smoking greatly reduces your risk of developing and dying from lung cancer.
    • Maintaining a healthy weight and being physically active cuts your risk of several cancers.
    • HPV vaccines prevent infection with the virus that causes most cervical cancers. And regular cervical cancer screening detects most cervical abnormalities so that they can be treated before they become cancer.
    • Colorectal cancer screening reduces the risk of developing and dying from colorectal cancer.
    • For women age 40 and older, getting regular mammograms reduces the chance of dying from breast cancer. (ongoing controversies ??)
    Myth––Your attitudes and beliefs can help you beat cancer. Unfortunately, despite many studies, this appears to be a myth. But a positive attitude may improve the quality of your life during and after treatment. Many people say that focusing on the joys in life and things that they can control helped them get through cancer treatment. Spending time with family and friends, taking part in hobbies and activities when possible, and enjoying the little things in life may help one better manage the stresses and worries of cancer.
    These are only some of the false and misleading ideas that can confuse and mislead people about the progress being made in cancer prevention, detection, and treatment. You can learn more from NCI about cancer prevention and screening.



    open access: BRCA1 is an essential regulator of heart function and survival following myocardial infarction (in research, references doxorubicin)



    Blogger's Note: technical paper, in research (eg. mice, tissue samples)

                              ~~~~~~~~~~~~~~~~~

    BRCA1 is an essential regulator of heart function and survival following myocardial infarction

    "BRCA1 mutation carriers, in addition to risk of breast and ovarian cancer, may be at a previously unrecognized risk of cardiac failure."

    FDA identifies more bogus cancer drugs (Avastin - labeled as Altuzan) in U.S | Reuters



    FDA identifies more bogus cancer drugs in U.S | Reuters


    Tue Apr 3, 2012 8:31pm EDT
     
    (Reuters) - The U.S. Food and Drug Administration on Tuesday said it has identified a new batch of counterfeit cancer drugs distributed in the United States and is urging doctors to avoid using the products, which contain no active ingredient.
    The fake versions of Swiss drugmaker Roche's widely used cancer drug Avastin are labeled as Altuzan, which is the brand name that Avastin is sold under in Turkey, and do not contain the drug's active ingredient, bevacizumab.

    Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review



     Blogger's Note: 2nd link JNCI

                      ~~~~~~~~~~~~~~~~

    Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review:

    Background
    MicroRNA (miR) expression may have prognostic value for many types of cancers. However, the miR literature comprises many small studies. We systematically reviewed and synthesized the evidence.

    Methods
    Using MEDLINE (last update December 2010), we identified English language studies that examined associations between miRs and cancer prognosis using tumor specimens for more than 10 patients during classifier development. We included studies that assessed a major clinical outcome (nodal disease, disease progression, response to therapy, metastasis, recurrence, or overall survival) in an agnostic fashion using either polymerase chain reaction or hybridized oligonucleotide microarrays.

    Results
    Forty-six articles presenting results on 43 studies pertaining to 20 different types of malignancy were eligible for inclusion in this review. The median study size was 65 patients (interquartile range [IQR] = 34–129), the median number of miRs assayed was 328 (IQR = 250–470), and overall survival or recurrence were the most commonly measured outcomes (30 and 19 studies, respectively). External validation was performed in 21 studies, 20 of which reported at least one nominally statistically significant result for a miR classifier. The median hazard ratio for poor outcome in externally validated studies was 2.52 (IQR = 2.26–5.40). For all classifier miRs in studies that evaluated overall survival across diverse malignancies, the miRs most frequently associated with poor outcome after accounting for differences in miR assessment due to platform type were let-7 (decreased expression in patients with cancer) and miR 21 (increased expression).

    Conclusions
    MiR classifiers show promising prognostic associations with major cancer outcomes and specific miRs are consistently identified across diverse studies and platforms. These types of classifiers require careful external validation in large groups of cancer patients that have adequate protection from bias.

    press release: Researchers discover a DNA marker (microRNA-16) that indicates if ovarian cancer treatment will be successful



    Researchers discover a DNA marker that indicates if ovarian cancer treatment will be successful

    Public release date: 3-Apr-2012

    Researchers discover a DNA marker that indicates if ovarian cancer treatment will be successful

    CHICAGO, IL – Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research have discovered that blood can help determine the best treatment plan for patients with ovarian cancer. More specifically, a genetic marker embedded in deoxyribonucleic acid (DNA), called microRNA, indicates if a patient with ovarian cancer has a benign or cancerous tumor, and that she will benefit from chemotherapy after surgery on the tumor. This data will be presented at the American Association for Cancer Research (AACR) Annual Meeting to be held from Saturday through Wednesday (March 31- April 4) in Chicago, IL.

    It is estimated that there will be 22,280 new cases and 15,500 deaths this year from ovarian cancer in the United States. Due to lack of adequate screening, the majority of patients with ovarian cancer are diagnosed at stage III (the second-to-last and most devastating stage of cancer), when 70 percent of these patients will die of their disease within 5 years.

    "The discovery that microRNAs can help predict the best treatment plan for women with ovarian cancer, who are most likely at stage III of the disease, offers them enormous hope," noted Iuliana Shapira, MD, director of the Cancer Genetics Program at the North Shore-LIJ Health System's Monter Cancer Center. "We can now inform patients at stage III ovarian cancer, if they will have success with chemotherapy following surgery, similar to patients who are at stage 1 disease. This information gives them hope that their disease is curable despite being diagnosed at an 'advanced stage.' It also gives them the strength necessary to undergo chemotherapy, which is a very invasive and toxic therapy necessary to obtain the cure." (Blogger's Note: a 'forward' looking statement; see text in red highlighted below)

    Several microRNAs have been found to have links with various types of cancer. The research conducted at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research found that microRNA-195 increased 40 fold during chemotherapy and microRNA-16 increased 80 fold during chemotherapy. These changes may explain why some patients with ovarian cancer have side effects of chemotherapy, why others become cured of cancer as a result of chemotherapy, and why others need ongoing chemotherapy to continue living with the cancer.

    "Understanding the changes in microRNA throughout chemotherapy treatment helps us better understand ovarian cancer and how best to treat patients who have this disease," said Annette Lee, PhD, associate investigator at the Feinstein Institute. "The genetic markers we identified allow patients to individualize their own therapy in order to have maximum benefit and minimal side effects. In addition, this knowledge will help researchers develop new treatments for patients with ovarian cancer."

    Dr. Shapira adds that, "We applied for a government grant and hope to receive the funds needed to validate these markers allow result in women receiving therapies that are more personalized and match their genetic makeup."

    open access: CLINICIAN'S CORNER - Management of Ovarian Cancer, April 4, 2012 — JAMA (clear cell/endometrioid)



    Management of Ovarian Cancer, April 4, 2012, — JAMA

    "Using the case of Ms W, we discuss the signs, symptoms, risk factors, and prognostic factors of epithelial ovarian cancer; review the evidence for surgical and postoperative medical management; and present the current recommendations for screening and follow-up......

    "A 75-Year-Old Woman Who Has Completed Treatment".......

    WebMD: Half of Cancer Survivors Die From Other Conditions



    Half of Cancer Survivors Die From Other Conditions

    website: NHANES - National Health and Nutrition Examination Survey Homepage



    NHANES - National Health and Nutrition Examination Survey Homepage

    press release: Nearly half of cancer survivors died from conditions other than cancer



    Blogger's Opinion:  while it is true that general health (patient/family physician connection) should be included in patients' wellness plans, this press release, does an injustice to cancer survivors who have have suffered, albeit longterm cancer survivors, as a result of treatment-related side effects/complications of which they may very well die (eg. connecting the dots - doxil/heart disease; Avastin/hypertension/bowel/intestinal complications.......); connecting the dots means would the patients have suffered apparent non-cancer related deaths if they had not had cancer/treatments; obviously important to actually read the research paper to elicit the details but the press release in itself is lacking in that it does not acknowledge the full patient experience; often research tries to 'dissect' the patient experience into bits and pieces and  parts which of course does not work, IMHO.
    Feel free to disagree and comment.

                                          ~~~~~~~~~~~~~

    Nearly half of cancer survivors died from conditions other than cancer

    CHICAGO -- Although cancer recurrence may be the overriding fear for many survivors, nearly half of survivors from a recently presented study died from other conditions.
    These results indicate survivors could potentially benefit from a more comprehensive, less cancer-focused approach to their health, according to lead researcher Yi Ning, M.D., Sc.D., assistant professor in the department of epidemiology and community health at Virginia Commonwealth University (VCU) and associate research member at VCU Massey Cancer Center in Richmond, Va. Ning presented the results at the AACR Annual Meeting 2012, held here March 31 - April 4.
    "We realized that the mortality rates for some types of cancer, such as breast cancer, had declined," said Ning. "Cancer survivors live much longer than they did several decades ago. So with this large group of cancer survivors, we need to pay more attention to cancer survivors' overall health."
    Ning and colleagues evaluated 1,807 cancer survivors who had participated in the National Health and Nutrition Examination Surveys (NHANES) study. The most common forms of cancer among the study group were breast, prostate, cervical, lung and colorectal.
    When originally surveyed through NHANES, a large percentage of the study group suffered from conditions other than cancer, including cardiovascular conditions, hypertension and diabetes.
    Researchers followed patients for more than 18 years. During the course of the study, 776 cancer survivors died. Fifty-one percent died from cancer and 49 percent died from other causes. Cardiovascular disease was the primary cause of noncancer deaths.
    Researchers found that the longer patients survived after their initial cancer diagnosis, the more likely they were to die from another disease: 32.8 percent died from another condition within five years of diagnosis compared with 62.7 percent after 20 years.
    With nearly half of cancer survivors dying from other causes, Ning said that physicians and patients must improve efforts to manage those risks.
    "After the detection of cancer, clinicians and cancer survivors pay less attention to the prevention and treatment of other diseases and complications," said Ning. "We shouldn't neglect other aspects of health because we are focused on cancer and overlook other chronic conditions."

    financial: Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --



    Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --

    "....Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas......"

    Vitamin B12’s reputation as an energizer exceeds evidence; deficiency rate is low - The Washington Post



    Vitamin B12’s reputation as an energizer exceeds evidence; deficiency rate is low - The Washington Post

    press release: Mayo Clinic study identifies optimal gene targets for new colon cancer test



    Blogger's Note: see other posting today on non-invasive testing for those at average risk/including link to the clinical trial

    Mayo Clinic study identifies optimal gene targets for new colon cancer test

    ROCHESTER, Minn. -- A study presented today by Mayo Clinic researchers at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago identified two genes that are optimal targets to be analyzed in a new noninvasive test for colorectal cancer developed by Mayo Clinic, in collaboration with Exact Sciences Corporation. The test uses a small sample of a patient's stool to check for specific DNA changes, known as gene methylation, that occur as cancer develops. The test can quickly detect both early stage cancer and precancerous polyps.

    Marshall Edwards Announces Data from Clinical Trial of ME-143 Selected for Presentation... -- SAN DIEGO, April 3, 2012 /PRNewswire/ --



    Marshall Edwards Announces Data from Clinical Trial of ME-143 Selected for Presentation... -- SAN DIEGO, April 3, 2012 /PRNewswire/ --

    Herbal Medicines Get Some More Respect - Health Blog - WSJ



    Herbal Medicines Get Some More Respect - Health Blog - WSJ

    Medscape: Bleeding Rates and Medical Costs of New Oral Anticoagulants (warfarin, dabigatran...)



    Bleeding Rates and Medical Costs of New Oral Anticoagulants

    April 2, 2012 (Chicago, Illinois) — Firsthand experience with the new oral anticoagulants, coupled with excitement over those yet to be widely in use, has inspired a range of studies examining real-world risk/benefits, as well as the potential costs of replacing warfarin with the new agents.

    In a poster session at last week's American College of Cardiology 2012 Scientific Sessions, investigators presented two separate experiences with dabigatran from different US centers--showing very different results--while others presented new cost analyses comparing different oral agents with warfarin.

    One US report of patients switched to dabigatran showed a much higher rate of major bleeding than in the RE-LY trial, but a lower rate of dyspepsia, while a second report showed a lower rate of both major and minor bleeding compared with RE-LY trial.

    Dr. Ronald D. Alvarez Elected 44th President of the Society of Gynecologic Oncology -- CHICAGO, April 3, 2012 /PRNewswire-USNewswire/ --



    Dr. Ronald D. Alvarez Elected 44th President of the Society of Gynecologic Oncology -- CHICAGO, April 3, 2012 /PRNewswire-USNewswire/ --

    media: (U.S.) Higher-Spending Hospitals Have Fewer Deaths for Emergency Patients



    Blogger's Note: a similar report from Canada was posted recently  (eg. higher spending hospitals)

    Higher-Spending Hospitals Have Fewer Deaths for Emergency Patients

    bloggers: Gregory D. Pawelski on Genomics And Targets For The Treatment Of Cancer: Is Our New World Turning Into "Pharmageddon" Or Are We On The Threshold Of Great Discoveries?



    Gregory D. Pawelski on Genomics And Targets For The Treatment Of Cancer: Is Our New World Turning Into "Pharmageddon" Or Are We On The Threshold Of Great Discoveries?

    "I was telling your old colleague, Dr. Herman Kattlove, who posted about this on his blog, I thought his "genetic heterogeneity" terminology was more befitting than what was used in the title of the British study (Intratumor Heterogeneity). "Taking one biopsy sample of a tumor may not be enough to reveal its full genetic identity," was described by Medical News Today's Catharine Paddock, PhD. The study is significant because it suggests relying on one sample could overlook (other) important biomarkers that help make tailored treatments effective, explaining perhaps why personalized cancer therapy has been less successful than expected. Dr. Robert Nagourney, Medical and Laboratory Director at Rational Therapeutics, Inc., Long Beach, California, pointed out the disturbing news regarding the predictive validity and clinical applicability of human tumor genomic analysis for the selection of (targeted) chemotherapeutic agents. He also pointed out the accompanying editorial by Dr. Dan Longo, which made several points worth noting. First, he states that "DNA is not the whole story." This should be familiar to those who follow cell function analysis. Dr. Longo references Albert Einstein, who said, "Things should be made as simple as possible, but not simpler." Dr. Nagourney appreciates and applauds Dr. Long's comments for they echo his sentiments completely. The article of the study is only the most recent example of a growing litany of observations that call into question molecular biologist's preternatural fixation on genomic analyses. Human biology is not simple and malignantly transformed cells more are more complex still. Investigators who insist upon using genomic platforms to force disorderly cells into artificially ordered sub-categories, have once again been forced to admit that these oversimplifications fail to provide the needed insights for the advancement of cancer therapeutics. Those laboratories and corporations that offer "high price" genomic analyses for the selection of "high price" chemotherapy drugs take notice of this and related articles carefully as these reports portend a troubling future for their current business model ("personalized" cancer treatment)."

    deadline April 18th: We’re Hiring: Web Development and Design Coordinator



    We’re Hiring: Web Development and Design Coordinator

    The Ovarian Cancer National Alliance is looking for a self-motivated individual with experience in web development, graphic design and web content management. The Web Development and Design Coordinator is responsible for designing and presenting content for the Alliance both online and in print. S/he manages online strategy development, maintains site standards, develops site promotions and works on online community and outreach campaigns.

    This position reports to the Marketing and Communications Manager and supports the work of other departments, including Public Policy, Development and Events.

    Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO Special Articles]



    Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO Special Articles]:

    pdf (open access)

    Purpose
    To provide recommendations for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer.

    Methods
    The American Society of Clinical Oncology convened a Panel of experts in medical and gynecologic oncology, clinical pharmacology, pharmacokinetics and pharmacogenetics, and biostatistics and a patient representative. MEDLINE searches identified studies published in English between 1996 and 2010, and a systematic review of the literature was conducted. A majority of studies involved breast, ovarian, colon, and lung cancers. This guideline does not address dosing for novel targeted agents.

    Results
    Practice pattern studies demonstrate that up to 40% of obese patients receive limited chemotherapy doses that are not based on actual body weight. Concerns about toxicity or overdosing in obese patients with cancer, based on the use of actual body weight, are unfounded.

    Recommendations
    The Panel recommends that full weight–based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure. There is no evidence that short- or long-term toxicity is increased among obese patients receiving full weight–based doses. Most data indicate that myelosuppression is the same or less pronounced among the obese than the non-obese who are administered full weight–based doses. Clinicians should respond to all treatment-related toxicities in obese patients in the same ways they do for non-obese patients. The use of fixed-dose chemotherapy is rarely justified, but the Panel does recommend fixed dosing for a few select agents. The Panel recommends further research into the role of pharmacokinetics and pharmacogenetics to guide appropriate dosing of obese patients with cancer.

    Patients Want Immediate Access to Radiology Test Results, Even if They’re Complicated and Contain Bad News - Wake Forest Baptist Medical Center



    Patients Want Immediate Access to Radiology Test Results, Even if They’re Complicated and Contain Bad News - Wake Forest Baptist Medical Center

    UK media: Ovarian cancer delays leading to big payouts for damages - including commentaries



    Ovarian cancer delays leading to big payouts for damages | Society | guardian.co.uk

    Exact Sciences website: (re: dna stool testing) Clinical Trial for average at risk patients



    Blogger's Note: there are no dates on some of the website's pages

    Clinical Trial

    DeeP-C (Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer)

    Exact Sciences is conducting a pivotal trial for the company’s multi-marker molecular diagnostic screening test for the early detection of colorectal cancer. The multi-center DeeP-C study will generate data to support Exact Sciences’ planned PMA submission to the U.S. Food and Drug Administration (FDA).  Exact Sciences is planning to have approximately 60 sites in the U.S. and Canada participate in the study. Those sites are expected to enroll more than 10,000 patients between the ages of 50 and 84 who are at average risk for colorectal cancer. For more information on the study please go to:
    www.clinicaltrials.gov

    Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer (DeeP-C)
    This study is currently recruiting participants.
    Verified August 2011 by Exact Sciences Corporation


    First Received on July 18, 2011.   Last Updated on March 30, 2012   History of Changes

    (excluded from trial (high risk):
    1. Subject has a family history of:
      • Familial adenomatous polyposis (also referred to as "FAP").
      • Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" or "Lynch Syndrome").
     

    The Exact CRC screening test is an investigational device and is not available for sale in the United States.

    Clinical Oncology News - Stool DNA Test Promising for Colorectal Screening



    Clinical Oncology News - Stool DNA Test Promising for Colorectal Screening

    "Stool DNA testing is moving the colorectal cancer (CRC) screening field a step closer to eradicating the disease, according to David Ahlquist, MD, Department of Gastroenterology and Hepatology at Mayo Clinic, Rochester, Minn., who helped develop this approach and presented recent findings at the 2012 Gastrointestinal Cancers Symposium.


    Stool DNA testing detects tumor-specific DNA alterations in cells that are continually being shed into the stool from precancerous and cancerous lesions. The test is now being developed by Exact Sciences, a molecular diagnostics company in Madison, Wis.

    The broad application of stool DNA testing in longitudinal screening programs is to prevent CRC through high precancer detection. In an invited lecture, Dr. Ahlquist said this claim is “not too bold and not hyperbole.” New-generation stool DNA testing, he said, offers “extraordinarily” high detection rates for curable cancers and precancers that are likely to progress. The test detects lesions on both sides of the colon with equal accuracy and reveals flat or serrated polyps likely to be missed by both fecal occult blood test and colonoscopy.
    The noninvasive DNA test involves no diet or medication restrictions, no bowel preparation and is done at home using a stool sample. “It is user-friendly, affordable and offers individuals unlimited access by mail,” he added............

    new WIKI website: Cowbird · FAQ



    Cowbird · FAQ
     

    Why do you call it Cowbird?

    We chose the name Cowbird to express the combined qualities of a cow and a bird.
    Cows are slow, steady, and grounded, while birds are fast, free, and full of joy.
    Most of the Internet — including websites like Facebook and Twitter — are all bird and no cow, while more traditional formats like novels and operas are all cow and no bird.
    Cowbird combines these two extremes to form a new kind of storytelling medium — mixing the slow, deeply rooted, contemplative idea of a cow with the fast, efficient, playful idea of a bird.

    abstract: Role of the Msh2 gene (Lynch Syndrome) in genome maintenance and development in mouse fetuses.



    Role of the Msh2 gene in genome maintenance and development in mouse fetuses

    These results indicate that elevated mutation levels have little effect on the development of the fetus, even if a mutator phenotype appears at the organogenesis stage.

     Abstract
    In an attempt to evaluate the roles of the mismatch repair gene Msh2 in genome maintenance and in development during the fetal stage, spontaneous mutations and several developmental indices were studied in Msh2-deficient lacZ-transgenic mouse fetuses.

    news: Increased risk of cardiovascular disease for relatives of cancer patients



    Increased risk of cardiovascular disease for relatives of cancer patients

     03 April 2012 Lund University
     
    A current study shows that the risk for coronary heart disease and stroke increases by almost thirty per cent in a person whose partner has cancer. The cause is probably the negative stress to which the cancer patient’s relative is exposed......

    Monday, April 02, 2012

    (financial news) Bionomics Limited : OPEN BRIEFING (Q&A)- CEO ON BNC105 OVARIAN CANCER TRIAL



    Bionomics Limited : OPEN BRIEFING - CEO ON BNC105 OVARIAN CANCER TRIAL

    Q. Why have you focused on ovarian cancer? 

    CEO & MD Deborah Rathjen
    "There is a clear unmet medical need for more effective systemic therapy. Despite modest
    improvements in patient outcomes as a result of surgery or platinum-based chemotherapy, the majority of ovarian cancer patients relapse and die of their disease.
    The impetus to focus on ovarian cancer as a clinical trial setting for BNC105 came from the preclinical data. The data showed firstly, a strong synergy of BNC105 with a class of cancer chemotherapy drugs called platins which are based on platinum and secondly, that BNC105 was effective and in fact very potent, in killing platin resistant as well as platin sensitive ovarian cancer cells in culture. Platinum-based drugs are used as part of the standard-of-care in the treatment of ovarian cancer, however, resistance to platinum-based therapy can develop quickly and both sets of data point to the potential of BNC105 in this setting.
    Ovarian cancer is the seventh leading cause of cancer-related death among Australian women. It is often diagnosed at an advanced stage after the cancer has spread beyond the ovary. In 2008 in Australia 1,272 ovarian cancer cases were diagnosed. The number of ovarian cancer cases in Australia increased by 47 percent between 1982 and 2006. It is anticipated that the number of new cases will continue to increase, with an estimated 1,488 women expected to be diagnosed with ovarian cancer in 2015. In 2010 there were an estimated 21,880 new cases and 13,850 deaths from ovarian cancer in the US. It is estimated that approximately US$2.2 billion is spent in the US each year on treating ovarian cancer..........


    Q. How relevant will the trials be for BNC105's potential application to other types of cancer? 

    CEO & MD Deborah Rathjen
    "Looking beyond ovarian cancer to the broader potential of BNC105, the platins include cisplatin and carboplatin. They are used in the treatment of a broad range of solid tumour types including lung, prostate, breast, melanoma and mesothelioma, hence the importance of combining BNC105 with these drugs as we are doing in the ovarian cancer trial. ......."

    Gene Maps Are No Cure-All - WSJ.com (references ovarian cancer as an example)



    Gene Maps Are No Cure-All - WSJ.com

    "The new study, published Monday in the journal Science Translational Medicine and presented at a meeting of the American Association for Cancer Research in Chicago, was based on data from thousands of twins in five countries. It found that for 23 of 24 diseases analyzed, most patients would get negative test results, suggesting that their risk of being stricken with these diseases is low.
    In reality, the study says, their risk would be only slightly lower than that of the general population. Patients who have been gene-sequenced, particularly without a doctor's counsel, could be lulled into a false sense of security.....

    "For example, one of the diseases studied was ovarian cancer. Dr. Vogelstein noted that of the 156 million or so women in the U.S., about 2.2 million are expected to get ovarian cancer at some point. But even if every woman got a whole-genome scan, the tests would be able to identify only 100,000 of them, Dr. Vogelstein said. "That tells you that 2.1 million women cannot be alerted to the fact that they will get the cancer," he said......

    Long-term Use of Estrogen Hormone Therapy Linked to Higher Risk for Breast Cancer « AACR News



    Long-term Use of Estrogen Hormone Therapy Linked to Higher Risk for Breast Cancer « AACR News


    • Risk increased as the duration of hormone therapy use increased.
    • Death rate from breast cancer did not increase with hormone therapy use.

    open access: Impaired Cognitive Function and Hippocampal Neurogenesis following Cancer Chemotherapy (Chemobrain)



     Blogger's Note: also refer to previous post regarding chemobrain research in mice, differences in the 2 studies include chemotherapy agents, but, same bottom line results (confirmation of side effects/adverse effects of chemotherapy treatments)

    Impaired Cognitive Function and Hippocampal Neurogenesis following Cancer Chemotherapy


    Conclusions (abstract): 
    Our results show that chronic treatment with either of two commonly used chemotherapeutic agents impairs cognitive ability and suggest that strategies to prevent or repair disrupted hippocampal neurogenesis may be effective in ameliorating this serious side effect in cancer survivors.

    open access: The Effects of Chemotherapy on Cognitive Function in a Mouse Model: A Prospective Study (Chemobrain)



    Blogger's Note:  note article for observations regarding duration of chemobrain/MRI imaging

    The Effects of Chemotherapy on Cognitive Function in a Mouse Model: A Prospective Study


    FYI: Ovarian Cancer and Us blog - most viewed by country (march 2012)





    #1 United States
    #2 France

    #3 Bulgaria

    #4 Russia

    #5 Canada

    #6 Germany

    #7 United Kingdom

    #8 Ireland

    #9 India

    #10 Brazil

    FYI: Ovarian Cancer and Us - most read this month (march 2012)